Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Sarcoma 1Genitourinary 1

Conditions

Water Intoxication 1Osteosarcoma 1Hematologic Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Acute Kidney Injury 1

Interventions

pertuzumab 3trametinib 2palbociclib 2dabrafenib 2copanlisib 2Trastuzumab 2Sunitinib 2Specimen Handling 2Sorafenib 2Oxaliplatin 2Nivolumab 2Magnetic Resonance Spectroscopy 2Leucovorin 2Immunoglobulin G 2HhAntag691 2Fluorouracil 2Disulfides 2Dasatinib 2Bevacizumab 2Afatinib 2Ado-Trastuzumab Emtansine 22C4 antibody 2venetoclax 1ulixertinib 1trastuzumab biosimilar HLX02 1temsirolimus 1sapanisertib 1ruxolitinib 1romidepsin 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × glucarpidase × Genitourinary × Clear all
NCT05899751 2024-05-10

Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate

BTG International Inc.

Unknown
1,000 enrolled
GenitourinaryOther hematologic neoplasmSarcoma

Osteosarcoma, Water Intoxication, Hematologic Neoplasms, Acute Kidney Injury, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡